Shares of PlusTherapeuticsInc . (NASDAQ:PSTV) rose 5.8% on Tuesday . The stock traded as high as $2.24 and last traded at $2.18, approximately 404,471 shares changed hands during trading. An increase of 43% from the average daily volume of 283,430 shares. The stock had previously closed at $2.06.
Separately, ValuEngine raised shares of PlusTherapeuticsInc . from a “hold” rating to a “buy” rating in a research report on Tuesday, September 24th.
The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 4.28. The stock has a 50 day moving average price of $2.41.
A hedge fund recently bought a new stake in PlusTherapeuticsInc . stock. Sabby Management LLC acquired a new position in PlusTherapeuticsInc . (NASDAQ:PSTV) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 113,600 shares of the company’s stock, valued at approximately $389,000. Sabby Management LLC owned 25.24% of PlusTherapeuticsInc . at the end of the most recent reporting period. Hedge funds and other institutional investors own 88.89% of the company’s stock.
About PlusTherapeuticsInc . (NASDAQ:PSTV)
Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, engages in developing treatments for cancer and other diseases in the United States. The company's lead product candidate in pipeline is DocePLUS, an albumin-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer.
Recommended Story: What is meant by holder of record?
Receive News & Ratings for PlusTherapeuticsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PlusTherapeuticsInc . and related companies with MarketBeat.com's FREE daily email newsletter.